Dry Eye | Disease Landscape and Forecast | G7 | 2020
Dry eye disease (DED) is a chronic, inflammatory, and highly heterogeneous condition of the eye; it is also referred to as dry eye syndrome or keratoconjunctivitis sicca. Although DED represents a large prevalent pool in the G7 markets, the condition is underdiagnosed and few drugs are approved to treat it. As such, commercial opportunity abounds in this space. Indeed, despite the challenges in drug development for DED, the pipeline is robust, with a number of drugs in active late-phase development. With the expected launch of six new drugs for DED and the generic entry of AbbVie’s blockbuster Restasis in the United States, the DED therapy market is set to be dynamic and competitive over the next decade.
QUESTIONS ANSWERED
- How large is the prescription drug-treatable DED population in the G7 countries? How will drug-treatment rates change over the 2019-2029 forecast period?
- What is the current size of the DED market for key prescription therapies in the G7 countries? How will key events, including the generic availability of Restasis in the United States, influence the market over the next decade?
- What is the current state of DED treatment? Which are the most important prescription drug classes / drugs and why? What are interviewed experts’ insights on current treatment options?
- What are the biggest areas of unmet need? Which late-phase therapies have the potential to fulfill these needs? What therapies of note are progressing in earlier phases?
CONTENT HIGHLIGHTS
Geographies: United States, EU5, Japan.
Primary research: 20 country-specific interviews with thought-leading ophthalmologists and optometrists. Supported by survey data collected for this and other DRG research.
Epidemiology: Total prevalence of DED by country, including diagnosed prevalence and prescription drug-treatment rates.
Forecast: 10-year, annualized, drug-level sales and patient share of key therapies for DED through 2029, segmented by brands / generics.
Emerging therapies: Phase III: 7 drugs; coverage of select Phase II drugs.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
